Cataracts Infantile

Ophthalmology
7
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
6
Early DiscoveryClinical DevelopmentMarket

On Market (6)

Approved therapies currently available

U
BYQLOVIApproved
clobetasol propionate
Unknown Company
ophthalmic2024
U
CLOBETASOL PROPIONATEApproved
clobetasol propionate
Unknown Company
topical2019
U
IMPEKLOApproved
clobetasol propionate
Unknown Company
topical2020
U
IMPOYZApproved
clobetasol propionate
Unknown Company
topical2017
U
OLUXApproved
clobetasol propionate
Unknown Company
topical2000
U
OLUX EApproved
clobetasol propionate
Unknown Company
topical2007

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Salvat
SalvatFL - Miami
1 program
1
Clobetasol PropionatePhase 31 trial
Active Trials
NCT05724446RecruitingEst. Dec 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
SalvatClobetasol Propionate

Clinical Trials (1)

NCT05724446SalvatClobetasol Propionate

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Start: Dec 2022Est. completion: Dec 2025
Phase 3Recruiting

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space